These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7993956

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Alterations in 8-hydroxy-2-(dipropylamino)tetralin-induced neuroendocrine responses after 5,7-dihydroxytryptamine-induced denervation of serotonergic neurons.
    Van de Kar LD, Li Q, Cabrera TM, Brownfield MS, Battaglia G.
    J Pharmacol Exp Ther; 1998 Jul; 286(1):256-62. PubMed ID: 9655867
    [Abstract] [Full Text] [Related]

  • 4. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion.
    Vicentic A, Li Q, Battaglia G, Van de Kar LD.
    Eur J Pharmacol; 1998 Apr 10; 346(2-3):261-6. PubMed ID: 9652368
    [Abstract] [Full Text] [Related]

  • 5. Chronic treatment with an anxiolytic dose of the 5-HT1A agonist ipsapirone does not alter ipsapirone acute neuroendocrine effects.
    Schmidt BH, Chaouloff F.
    Psychoneuroendocrinology; 1993 Apr 10; 18(7):457-66. PubMed ID: 7903466
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI).
    Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA, van de Kar LD.
    J Pharmacol Exp Ther; 1993 Aug 10; 266(2):836-44. PubMed ID: 8394920
    [Abstract] [Full Text] [Related]

  • 7. Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins.
    Raap DK, Garcia F, Muma NA, Wolf WA, Battaglia G, van de Kar LD.
    J Pharmacol Exp Ther; 1999 Feb 10; 288(2):561-7. PubMed ID: 9918559
    [Abstract] [Full Text] [Related]

  • 8. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.
    Li Q, Rittenhouse PA, Levy AD, Alvarez Sanz MC, Van de Kar LD.
    Neuropharmacology; 1992 Oct 10; 31(10):983-9. PubMed ID: 1359439
    [Abstract] [Full Text] [Related]

  • 9. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects.
    Berlin I, Warot D, Legout V, Guillemant S, Schöllnhammer G, Puech AJ.
    Clin Pharmacol Ther; 1998 Apr 10; 63(4):428-36. PubMed ID: 9585797
    [Abstract] [Full Text] [Related]

  • 10. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.
    Levy AD, Li Q, Van de Kar LD.
    Neuropharmacology; 1994 Apr 10; 33(3-4):335-42. PubMed ID: 7984271
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear.
    Rittenhouse PA, Bakkum EA, O'Connor PA, Carnes M, Bethea CL, van de Kar LD.
    Brain Res; 1992 May 15; 580(1-2):205-14. PubMed ID: 1354556
    [Abstract] [Full Text] [Related]

  • 13. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
    Schreiber R, De Vry J.
    Eur J Pharmacol; 1993 Nov 16; 249(3):341-51. PubMed ID: 7904566
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat.
    Baudrie V, De Vry J, Broqua P, Schmidt B, Chaouloff F, Glaser T.
    Eur J Pharmacol; 1993 Feb 16; 231(3):395-406. PubMed ID: 8095465
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, Sommermeyer H, Glaser T.
    J Pharmacol Exp Ther; 1998 Mar 16; 284(3):1082-94. PubMed ID: 9495870
    [Abstract] [Full Text] [Related]

  • 18. 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge.
    Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME.
    Neuropsychopharmacology; 1999 Jun 16; 20(6):628-39. PubMed ID: 10327431
    [Abstract] [Full Text] [Related]

  • 19. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses.
    Bagdy G.
    Behav Brain Res; 1996 Jun 16; 73(1-2):277-80. PubMed ID: 8788518
    [Abstract] [Full Text] [Related]

  • 20. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E, Goldstein M, Bohmaker K.
    Mol Pharmacol; 1990 Feb 16; 37(2):231-7. PubMed ID: 1968223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.